Chemours shareholders elect 11 directors, approve 2026 equity plan and say-on-pay
At its April 24, 2026 annual meeting, Chemours shareholders re-elected all eleven director nominees to one-year terms, approved an advisory say-on-pay vote, and approved the 2026 Equity and Incentive Plan. Shareholders also ratified PricewaterhouseCoopers LLP as the independent auditor. The plan reserves up to 6,375,275 shares for employee, contractor and director awards, which dilutes existing holders only as those shares are issued.
Key points
- All 11 director nominees elected to one-year terms; George R. Brokaw received 95.8% of votes cast, while the other nominees each received between 98.1% and 99.3%.
- Say-on-pay advisory vote approved: 110,058,427 for and 2,527,583 against.
- 2026 Equity and Incentive Plan approved: 108,842,885 for and 3,734,567 against, reserving up to 6,375,275 shares.
- PricewaterhouseCoopers LLP ratified as independent registered public accounting firm: 128,312,790 for and 813,925 against.
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.